← Back to guidelines
Allergy & Immunology35 papers

Infection caused by Nipah virus

Last edited: 4/14/2026

Overview

Nipah virus (NiV) is a highly lethal zoonotic pathogen causing severe neurological disease with high mortality rates, posing significant threats to human and animal health 123. No proven post-exposure treatments exist, highlighting the urgent need for vaccine development 1.

Diagnosis

  • Clinical presentation includes fever, headache, altered mental status, and respiratory symptoms 5.
  • Laboratory confirmation involves RT-PCR testing of respiratory, cerebrospinal, or blood samples 5.
  • Serological testing for NiV-specific antibodies can aid in diagnosis, particularly in later stages 5.
  • Management

  • Currently, no specific antiviral treatments are available; management focuses on supportive care including mechanical ventilation, fluid management, and prevention of secondary infections 5.
  • Monoclonal antibodies and early diagnosis through Point of Care assays have shown promise in improving outcomes 5.
  • Intensive care unit (ICU) support is crucial for severe cases 5.
  • Special Populations

  • Pregnancy: Specific management guidelines are not provided in the abstracts 5.
  • Pediatrics: No distinct pediatric management strategies are detailed; supportive care remains central 5.
  • Elderly: Higher mortality rates are noted, emphasizing the need for aggressive supportive care 5.
  • Comorbidities: Patients with underlying health conditions may require tailored supportive care to manage complications 5.
  • Key Recommendations

  • Develop and implement multi-epitope based vaccines targeting NiV structural proteins for broad population coverage (Evidence: Expert opinion) 13.
  • Utilize immunoinformatics and molecular modeling approaches to design stable and immunogenic vaccine constructs capable of interacting with TLR receptors (Evidence: Expert opinion) 23.
  • Enhance surveillance and rapid diagnostic capabilities, including Point of Care assays and monoclonal antibodies, to improve outbreak containment and patient outcomes (Evidence: Moderate) 5.
  • References

    1 Sharma S, Yadav PD, Cherian S. Comprehensive immunoinformatics and bioinformatics strategies for designing a multi-epitope based vaccine targeting structural proteins of Nipah virus. Frontiers in immunology 2025. link 2 Masum MHU, Mahdeen AA, Barua L, Parvin R, Heema HP, Ferdous J. Developing a chimeric multiepitope vaccine against Nipah virus (NiV) through immunoinformatics, molecular docking and dynamic simulation approaches. Microbial pathogenesis 2024. link 3 Banico EC, Sira EMJS, Fajardo LE, Dulay ANG, Odchimar NMO, Simbulan AM et al.. Advancing one health vaccination: In silico design and evaluation of a multi-epitope subunit vaccine against Nipah virus for cross-species immunization using immunoinformatics and molecular modeling. PloS one 2024. link 4 Shahab M, Iqbal MW, Ahmad A, Alshabrmi FM, Wei DQ, Khan A et al.. Immunoinformatics-driven In silico vaccine design for Nipah virus (NPV): Integrating machine learning and computational epitope prediction. Computers in biology and medicine 2024. link 5 Sahay RR, Yadav PD, Gupta N, Shete AM, Radhakrishnan C, Mohan G et al.. Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India. Epidemiology and infection 2020. link

    Original source

    1. [1]
    2. [2]
    3. [3]
    4. [4]
      Immunoinformatics-driven In silico vaccine design for Nipah virus (NPV): Integrating machine learning and computational epitope prediction.Shahab M, Iqbal MW, Ahmad A, Alshabrmi FM, Wei DQ, Khan A et al. Computers in biology and medicine (2024)
    5. [5]
      Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India.Sahay RR, Yadav PD, Gupta N, Shete AM, Radhakrishnan C, Mohan G et al. Epidemiology and infection (2020)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG